Home page
05 dicembre 2020
Scientific Activities
Carbohydrate Science Group
Research Activity
Collaborations with institutions
Major Equipments
Selected Pubblications
NMR Center
Synthesis Group
Analytical Service
Selected Pubblications Carbohydrate Group

Selected publications 2007-2009:

- Correspondence on“Oversulfated chondroitin sulfate is not the sole contaminant in heparin”. M. Guerrini, Z. Shriver, A. Naggi, B. Casu, R. J. Linhardt, G. Torri & R. Sasisekharan. Nature Biotechnol. (2010) Vol 28, 207-211 

- Glycosaminoglycan origin and structure revealed by a multivariate analysis of NMR and CD spectra. Rudd TR, Skidmore MA, Guidmond SE, Cosentino C, Torri G, Fernig DG, Lauder RM, Guerrini, M and Yates EA. Glycobiology 2009;19:52-67.

- Non-anticoagulant heparins and inhibition of cancer. Casu B, Vlodavsky I, and Sanderson RD... Pathophysiol Hemost Thromb 2008; 36:195-203.

- Surface functionalization of cotton cellulose with glycidyl methacrylate and its application for the adsorption of aromatic pollutants from wastewaters Vismara E, Melone L, Gastaldi G, Cosentino C, Torri G.. Journal of hazardous materials 2009;170(2-3):798-808.

- Alpha cellulose from industrial and agricultural renewable sources like short flax fibres, ears of corn and wheat-straw and its transformation into cellulose acetates. Vismara E, Gastaldi G, Valerio A, Bertini S, Cosentino C and Eisele G.  J. Mater. Chem., 2009, 19: 8678 - 8686, DOI: 10.1039/b911610a

- Minimum FGF2 binding structural requirements of heparin and heparansulfate oligosaccharides as determined by NMR spectroscopy. Guglieri S, Hricovini M, Ramn R, Polito L, Torri G, and Casu B.  Biochemistry 2008, 7:13862-13869.

- Antithrombin-binding octasacchides and roles of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Guerrini M, Guglieri S, Casu B, Torri G, Boudier C, and Viskov C.  J Biol Chem 2008, 283:26662-26675.

- Unusual partially O-methylated alpha-galactan from mushrooms of the genus Pleorotus. E. R. Carbonero, A.H. Gracher, M.C. Rosa, G. Torri, G.L. Sassaki, P.A. Gorin, M. Iacomini.  Phytochemistry, 2008; 69: 252-257.

- Heparanase, heparin and the coagulation system in cancer progression. Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B, and Sasisekharan R.  Thromb Res 2007; 120(2):112-120.

- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Yang Y, McLeod V, Day J, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R,  Naggi A, Torri, G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yacobby S, Shaughnessy JD,  Bartologie B, and Sanderson RD.  Blood, 2007; 110: 2041-2048.

- Interaction of heparins with fibroblast growth factors: conformational aspects. Guerrini M, Hricovini M, and Torri G.  Current Pharm Des, 2007; 13: 2045-2056.

- Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.  Vlodavsky I, Ilan N, Naggi A, and Casu B. Current Pharm Des 2007;13: 2057-2073.